Prescribing information is available at the end of this presentation
JXT-004 Jext EAACI 2011 visual aid
Jext adrenaline delivery
in the heart-pounding panic
of anaphylaxis
ADRENALINE PENS SHOULD BE RELIABLE
Current standard treatment has a shelf life of 18 months, requires storage
below 25oC and protection from light at all times.1
Approximately 1/3 of patients fail to replace their pens within 18 months.2
- a significant percentage of patients carry emergency rescue medication which cannot be guaranteed effective
Jext is reliable
due to long shelf life
and simple storage
upgrade reliability
Jext has a 24-month shelf life.3
Jext is effective above 25oC and does not require
protection from light.3
Every Jext comes with a robust, protective carry case.
Jext
Current standard of care
18
months
Maximum shelf-life from date of manufacture
24
months
ADRENALINE PENS SHOULD BE EASY TO USE
Currently available adrenaline pens have disadvantages that
may limit their use and effectiveness.4-6
O
nly 30–44% of patients were able to demonstrate correct
Adrenaline Auto-Injector (AAI) technique.7
Jext is easy
to use due to
intuitive design
upgrade ease of use
C
lear labelling.
- Same two activation steps as current standard of care3
Illustrated instructions for use and directional arrows.
C
olour coded ends.
- Yellow safety cap
- Black needle end
Despite training with current standard treatments, accidents happen
and lives are at risk.
M
ore than 15,000 unintentional injections with adrenaline pens
have been reported from 1994-2007.8
Jext is designed
to deliver adrenaline
correctly
upgrade correct usage
11.64mm +-0-80
Cartridge AAIs appear to be significantly more capable of consistently
delivering a quick, clinically relevant dose of I.M. adrenaline than
syringe AAIs.4
21.09mm +-2.54
ADRENALINE SHOULD BE DELIVERED CORRECTLY
P<0.01 Cartridge vs Syringe AAI
Jext is designed
to deliver adrenaline
correctly
upgrade correct usage
Jext is a cartridge based device that administers adrenaline intramuscularly,
ensuring rapid peak plasma concentration.3,4
Jext has colour coded ends to safeguard against accidental injection.3
- Yellow safety cap
- Black needle end
Jext has unique needle protection.3
- The Jext needle shield covers the needle and locks after injection,3 reducing the risk of subsequent needlestick injury
lifetime care and support
in anaphylaxis
TO INCREASE THE CHANCES OF SURVIVING POTENTIALLY FATAL ANAPHYLAXIS,
REGULAR TRAINING IN CORRECT AAI USE IS NEEDED7
Comprehensive training and free support materials
for healthcare professionals and patients:
Instructional video
Downloadable resources
Expiry alert service
Jext Simulator
To find out more go to www.life-saver.org
upgrade correct usage
UPGRADING TO JEXT COULDN’T BE SIMPLER
Jext has the same two activation steps as current standard of care.1,3
This may assist patients who have previously used an AAI in understanding how to use Jext.
Use the Jext Simulator to demonstrate how easy it is to use Jext.
Jext the new standard of care
for anaphylaxis based on more
than a decade of experience with
adrenaline auto-injectors
RELIABLY
L
ongest shelf life
E
ffective above 25oC
EASILY
C
lear labelling
S
imple instructions
CORRECTLY
Intramuscular delivery
Lifesaver training programme
Jext ® Auto-Injector abbreviated prescribing information.
Presentation: Jext is a single-use, cartridge based adrenaline auto-injector designed for
easy use. Jext 300 micrograms, delivers a single dose of 0.30ml of adrenaline (as tartrate),
in a sterile solution. 1.1ml of adrenaline remains in the auto-injector after activation. Jext
150 micrograms delivers a single dose of 0.15ml of adrenaline (as tartrate) in a sterile
solution. 1.25ml of adrenaline remains in the auto-injector after activation. The inspection
window in the label is filled by a coloured plastic rod (white in Jext 300 and blue in Jext
150) to confirm that the auto-injector has activated and the adrenaline solution has been
injected. Indication: Jext is indicated in the emergency treatment of severe acute allergic
reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as
idiopathic or exercise induced anaphylaxis. Dosage: ADULTS: Single use, self administration
of 0.30ml adrenaline (Jext 300 micrograms) intramuscularly. CHILDREN: The appropriate
dosage may be 0.15ml (Jext 150 micrograms) for children 15–30kg body weight and 0.30ml
(Jext 300 micrograms) adrenaline for children >30kg body weight, or at the discretion of
the physician. Administration: Jext is operated by simply pressing the black injector tip
against the outer (anterolateral) thigh. This will activate a plunger, which pushes a concealed
needle through the membrane on the black injector tip into the muscle and injects a dose of
adrenaline. The yellow cap prevents the device from activating, and should not be removed
before injection is required. The black injector tip should be kept away from the hand.
Jext is designed to inject through clothing or directly through the skin. After administration
massage around the injection area is advised to accelerate absorption. In the absence of
clinical improvement or if deterioration occurs, a second injection with an additional Jext
may be administered 5–15 minutes after the first injection. As Jext is designed for emergency
treatment, the patient should always seek immediate medical attention even if symptoms
have disappeared. Contra-indications: There are no absolute contraindications to the
use of Jext during an allergic emergency. Warnings: Jext should only be administered
into the outer (anterolateral) thigh. Avoid the risk of inadvertent intravascular injection.
DO NOT INJECT INTO THE BUTTOCKS. Accidental injection into the hands or feet may result
in loss of blood flow to the affected areas. Precautions: All patients who are prescribed
Jext should be thoroughly instructed to understand the indications for use and the correct
method of administration. Caution is indicated in patients receiving drugs that may sensitise
the heart to arrhythmias, including digitalis and quinidine. The effects of adrenaline may
be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors (MAO-inhibitors)
and catechol-O-methyl transferase inhibitors (COMT inhibitors). Adrenaline should be used
in pregnancy only if the potential benefit justifies any potential risk to the foetus. Adverse
events: May include palpitations, tachycardia, nausea and vomiting, respiratory difficulty,
headache, dizziness and anxiety. Cardiac arrhythmias may follow administration of
adrenaline. Overdoses of adrenaline may cause cerebral haemorrhage or arrhythmias.
Shelf life: 2 years. Replace and discard the pre-filled pen if the solution is discoloured
or contains a precipitate, or at the latest before the expiry date. The expiry date is indicated
on the label and Jext should not be used after this date. Storage conditions: Do not
freeze. Legal Category: POM Marketing Authorisation Numbers: PL 10085/0052.
PL 10085/0053 Marketing Authorisation holder: ALK Abelló A/S, Bøge Alle 6-8,
DK-2970 Hørsholm. Date of last revision: September 2010.
References
1. EpiPen SmPC. Electronic Medicines Compendium (www.emc.medicines.org.uk).
2. Lombardelli S. Adrenaline auto-injectors. How effective are written patient instructions when used
alone in a simulated self-administration test? Poster presented at The British Society of Allergy and Clinical Immunology, 2009.
3. Jext SmPC. Electronic Medicines Compendium (www.emc.medicines.org.uk).
4. Schwirtz A, Seeger H. Are adrenaline auto-injectors fit for purpose? A pilot study of the mechanical
and injection performance characteristics of a cartridge- versus a syringe-based autoinjector.
J Asthma Allergy 2010;3:159–167.
5. Mehr S, Robinson M, Tang M. Doctor – How do I use my EpiPen? Pediatr Allergy Immunol 2007;18(5):
448–452.
6. Song TT, Nelson MR, Chang JH et al. Adequacy of the epinephrine autoinjector needle length in delivering epinephrine to the intramuscular tissues. Ann Allergy Asthma Immunol 2005;94(5):539–542.
7. Frew AJ. What are the ‘ideal’ features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis? Allergy 2011;66(1):15–24.
8. Simons FE, Edwards ES, Read EJ Jr et al. Voluntarily reported unintentional injections from epinephrine
auto-injectors. J Allergy Clin Immunol 2010;125(2):419–423.